Abdollah, Vahid
Noamani, Alireza
Ralston, John
Ho, Chester
Rouhani, Hossein
Funding for this research was provided by:
Mitacs (RES0051444)
Article History
Received: 18 May 2023
Accepted: 18 December 2023
First Online: 2 January 2024
Declarations
:
: The Research Ethics Board of the University of Alberta approved the study (Pro00104153). All participants provided written informed consent before participation.
: VA, AN, CH, and HR report no declarations of interest. John Ralston is the CEO of Neursantys Inc. (formally known as PROTXX Medical Ltd). The authors report no other potential conflicts of interest in this work.